A detailed history of Flaharty Asset Management, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Flaharty Asset Management, LLC holds 1,116 shares of LLY stock, worth $887,967. This represents 0.15% of its overall portfolio holdings.

Number of Shares
1,116
Previous 1,124 0.71%
Holding current value
$887,967
Previous $1.02 Million 2.85%
% of portfolio
0.15%
Previous 0.16%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$772.14 - $960.02 $6,177 - $7,680
-8 Reduced 0.71%
1,116 $988,000
Q2 2024

Aug 01, 2024

BUY
$724.87 - $909.04 $15,222 - $19,089
21 Added 1.9%
1,124 $1.02 Million
Q1 2024

May 14, 2024

SELL
$592.2 - $792.28 $116,071 - $155,286
-196 Reduced 15.09%
1,103 $858,000
Q4 2023

Feb 05, 2024

SELL
$525.19 - $619.13 $88,757 - $104,632
-169 Reduced 11.51%
1,299 $757,000
Q3 2023

Nov 14, 2023

BUY
$434.7 - $599.3 $53,902 - $74,313
124 Added 9.23%
1,468 $788,000
Q2 2023

Aug 10, 2023

SELL
$350.74 - $468.98 $8,417 - $11,255
-24 Reduced 1.75%
1,344 $630,000
Q1 2023

May 10, 2023

BUY
$310.63 - $364.82 $17,705 - $20,794
57 Added 4.35%
1,368 $469,000
Q4 2022

Feb 14, 2023

BUY
$321.55 - $374.67 $7,717 - $8,992
24 Added 1.86%
1,311 $479,000
Q3 2022

Nov 02, 2022

SELL
$296.48 - $337.87 $93,687 - $106,766
-316 Reduced 19.71%
1,287 $416,000
Q1 2022

May 03, 2022

BUY
$234.69 - $291.66 $13,612 - $16,916
58 Added 3.75%
1,603 $459,000
Q4 2021

Feb 15, 2022

SELL
$224.85 - $279.04 $27,206 - $33,763
-121 Reduced 7.26%
1,545 $427,000
Q3 2021

Nov 02, 2021

SELL
$221.6 - $272.71 $26,813 - $32,997
-121 Reduced 6.77%
1,666 $385,000
Q1 2021

May 11, 2021

SELL
$164.32 - $212.72 $9,037 - $11,699
-55 Reduced 2.99%
1,787 $334,000
Q4 2020

Feb 03, 2021

BUY
$130.46 - $172.63 $240,307 - $317,984
1,842 New
1,842 $311,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Flaharty Asset Management, LLC Portfolio

Follow Flaharty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Flaharty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Flaharty Asset Management, LLC with notifications on news.